108620-55-9

Basic information

• Product Name: Ethyl 3'-nitro-[1,1'-biphenyl]-4-carboxylate
• Synonyms: Ethyl 3'-nitro-[1,1'-biphenyl]-4-carboxylate;Ethyl 4-(3-nitrophenyl)benzoate
• CAS NO: 108620-55-9
• Molecular Formula: C15H13NO4
• Molecular Weight: 271.26802
• Mol File: 108620-55-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethyl 3'-nitro-[1,1'-biphenyl]-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 3'-nitro-[1,1'-biphenyl]-4-carboxylate(108620-55-9)
• EPA Substance Registry System: Ethyl 3'-nitro-[1,1'-biphenyl]-4-carboxylate(108620-55-9)

Safety Data

• Hazardous Substances Data: 108620-55-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Ethyl 3'-nitro-[1,1'-biphenyl]-4-carboxylate is utilized as a key intermediate in organic synthesis for the creation of a variety of chemical compounds. Its unique structure allows for further functionalization and modification, making it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Ethyl 3'-nitro-[1,1'-biphenyl]-4-carboxylate serves as a precursor in the development of new drug molecules. Its presence in the molecular structure can influence the pharmacological properties of the final drug, contributing to its therapeutic effects and potential applications in medicine.
Used in Medicinal Chemistry:
Ethyl 3'-nitro-[1,1'-biphenyl]-4-carboxylate is employed as a building block in medicinal chemistry for the design and synthesis of bioactive compounds. Its incorporation into molecular frameworks can enhance the biological activity and selectivity of drug candidates, leading to the discovery of novel therapeutic agents.
Used in Drug Development:
In drug development, Ethyl 3'-nitro-[1,1'-biphenyl]-4-carboxylate is used as a starting material for the synthesis of potential drug candidates. Its versatile chemical properties enable the exploration of new chemical space and the optimization of drug-like properties, such as solubility, stability, and bioavailability.
Used in Chemical Industry:
Ethyl 3'-nitro-[1,1'-biphenyl]-4-carboxylate finds applications in the chemical industry for the production of various organic materials and specialty chemicals. Its unique structure and reactivity contribute to the development of new materials with specific properties and applications in areas such as coatings, polymers, and advanced materials.

Upstream product

• 5798-75-4 Ethyl 4-bromobenzoate 
• 13331-27-6 m-nitrobenzene boronic acid 
• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 98-95-3 nitrobenzene 
• 32848-24-1 ethyl 4-(((nonafluorobutyl)sulfonyl)oxy)benzoate 
• 64-17-5 ethanol 
• 5737-85-9 3'-nitro-biphenyl-4-carboxylic acid 

Relevant articles and documents

METHOD OF TREATMENT AND DEVICE

A method and an angioplasty balloon catheter used in a method of preventing or minimizing incidence of neointimal hyperplasia (NIH) in a blood vessel of an animal following angioplasty treatment. The method comprising locating the angioplasty balloon cath

Suzuki-Miyaura reaction catalyzed by graphene oxide supported palladium nanoparticles

Pd supported on polyamine modified graphene oxide (GO-NH 2-Pd2 +) was fabricated for the first time. The prepared catalyst was characterized by transmission electron microscopy, X-ray diffraction spectroscopy, X-ray photoelectron spectroscopy and infrared spectroscopy. The catalytic activity of the prepared catalyst was investigated by employing Suzuki-Miyaura coupling reaction as a model reaction. A series of biphenyl compounds were synthesized through the Suzuki-Miyaura reaction using GO-NH2-Pd2 + as catalyst. The yields of the products were in the range from 71% to 95%. The catalyst can be readily recovered and reused at least 10 consecutive cycles without significant loss its catalytic activity.

Conformational analogues of Oxamflatin as histone deacetylase inhibitors

Conformational analogues of the hydroxamic acid Oxamflatin 1 - compounds 3a, 3b and 4 - have been synthesised to enable evaluation of the impact of varying the linking section on histone deacetylase inhibition. Preliminary testing indicates treatment of l

Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents

The present invention provides compounds having the formula: wherein n is0or1; R is —NH2or wherein R1and R2are independently selected from the group consisting of H, alkyl, aralkyl, heteroaralkyl, carboxy, carboxyalkyl, and carbamoyl; Q is R3C(O)— or wherein R5is selected from the group consisting of H, alkyl, aralkyl, heteroaralkyl, and carbamoylalkyl, and R3and R4are selected from the group consisting of H, alkyl, alkoxy, arylalkoxy, aralkyl, heteroaralkyl, and carbamoylalkyl; the Q—NH—(CH2)n— and the —C(O)R substituents of the compound of formula I are independently positioned ortho, meta, orpara relative to the carbon atoms that form the bond between the two phenyl groups to which said substituents are bound, with the proviso that said substituents are not both positioned ortho; and the Q—NH—(CH2)nand the —C(O)R substituents of the compound of formula II are positioned meta orpara to each other; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. The compounds are useful for treating uPA- or uPAR-mediated disorders, e.g., tumor metastasis, tumor angiogenesis, restenosis, chronic inflammation, or corneal angiogenesis.